SCHEMBL291054

SCHEMBL291054

CC1CCC(C(C)C)C(C(=O)Nc2ccc(CC#N)cc2)C1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.65
EPHX1 P07099 1/20 0.43
KMT2A Q03164 3/20 0.42
SERPINE1 P05121 2/20 0.41
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
P2RX4 Q99571 1/20 0.39
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
GAA P10253 1/20 0.39
RECQL P46063 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NPC1 O15118 3/20 0.38
RAB9A P51151 2/20 0.38
THRB P10828 1/20 0.38
TRPV1 Q8NER1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31438756 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL16551709 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL4127806 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL16004827 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL3219019 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL584077 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL10044268 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL16551708 1.00 TRPM8 (0.65) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL18812290 0.89 TRPM8 (0.62) TRPM8EPHX1KMT2ASERPINE1MEN1
SCHEMBL2628763 0.86 TRPM8 (0.70) TRPM8EPHX1KMT2ASERPINE1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028893-A Composition and method for producing the same 奇华顿股份有限公司 2026-05-12 CN claimed
EP-3817575-B1 SOLUBILISATION OF COOLING AGENTS OF LOW SOLUBILITY SYMRISE AG (DE) 2025-10-15 EP claimed
US-12414906-B2 Compositions and methods for treating hot flashes THE PROCTER & GAMBLE COMPANY (US) 2025-09-16 US claimed
US-20250163006-A1 New Coolants, and Preparations Containing Same SYMRISE AG (DE) 2025-05-22 US claimed
WO-2025078256-A1 COMPOSITION GIVAUDAN SA (CH) 2025-04-17 WO claimed
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same SYMRISE AG (DE) 2025-02-27 US claimed
WO-2025026525-A1 HETEROCYCLIC COMPOUNDS AS PHYSIOLOGICAL COOLANTS SYMRISE AG (DE) 2025-02-06 WO claimed
EP-4469439-A1 NEW COOLANTS, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-12-04 EP claimed
EP-4452941-A1 ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME Symrise AG (DE) 2024-10-30 EP claimed
CN-118829416-A Composition (III) 西姆莱斯股份公司 2024-10-22 CN claimed
EP-2168957-A2 Alkyl-substituted tetrahydropyranes as aromatic materials Symrise GmbH & Co. KG (DE) 2010-03-31 EP claimed
EP-2162018-A1 SALT ENHANCEMENT Givaudan SA (CH) 2010-03-17 EP claimed
WO-2009140783-A1 COOLING COMPOSITION GIVAUDAN SA (CH) 2009-11-26 WO claimed
US-20090240223-A1 ABSORBENT ARTICLE COMPRISING LOTION COMPOSITION COMPRISING A COOLING AGENT PROCTER & GAMBLE COMPANY, THE 2009-09-24 US claimed
WO-2009105740-A2 ABSORBENT ARTICLE COMPRISING LOTION COMPOSITION COMPRISING A COOLING AGENT THE PROCTER & GAMBLE COMPANY (US) 2009-08-27 WO claimed
US-20080311266-A1 Salt Enhancement GRAY KIMBERLEY H 2008-12-18 US claimed
WO-2008148234-A1 SALT ENHANCEMENT GIVAUDAN SA (CH) 2008-12-11 WO claimed
WO-2008138162-A1 COMPOSITIONS AND THEIR USE GIVAUDAN SA (CH) 2008-11-20 WO claimed
US-7414152-B2 e. g. N-(4-cyanomethylphenyl) p-menthanecarboxamide; cooling agent in cosmetics and food industries; with additional cooling compound such as menthol, menthone, isopulegol GIVAUDAN, SA (CH) 2008-08-19 US claimed
US-20060276667-A1 N-substituted p-menthane carboxamides GIVAUDAN-SA 2006-12-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276667-A1 N-substituted p-menthane carboxamides ME2, ME3, PYM1 TRPM8 45/4885EPHX1 268/4885KMT2A 906/4885
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same TAS2R5, TAS2R7, TAS2R8 TRPM8 363/4885EPHX1 2617/4885KMT2A 2748/4885
US-12414906-B2 Compositions and methods for treating hot flashes ELOVL5, ELOVL3, HCN3 TRPM8 672/4885EPHX1 1620/4885KMT2A 4355/4885
US-20250163006-A1 New Coolants, and Preparations Containing Same TTR, TAS2R5, TAS2R50 TRPM8 152/4885EPHX1 2081/4885KMT2A 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.